Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972729 | 0.85 | SMN1; SMN2 (0.65) | LMNAMAPTALOX12KMT2ASMN1; SMN2 | |
| SCHEMBL25474694 | 0.83 | TRPV1 (0.43) | LMNAMAPTALOX12KMT2ASMN1; SMN2 | |
| SCHEMBL25474698 | 0.83 | EPHX1 (0.53) | LMNAMAPTSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL9453900 | 0.81 | SMN1; SMN2 (0.51) | LMNAMAPTALOX12SMN1; SMN2ALDH1A1 | |
| SCHEMBL15739655 | 0.79 | P2RY6 (0.75) | LMNAMAPTALOX12KMT2ASMN1; SMN2 | |
| SCHEMBL21338327 | 0.78 | LMNA (0.51) | LMNAMAPTALOX12KMT2ASMN1; SMN2 | |
| SCHEMBL3976381 | 0.77 | ALDH1A1 (0.58) | LMNAMAPTALOX12KMT2ASMN1; SMN2 | |
| SCHEMBL24778058 | 0.75 | RAB9A (0.61) | MAPTSMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL25473525 | 0.74 | HDAC3 (0.57) | MAPTSMN1; SMN2GAA | |
| SCHEMBL24312063 | 0.73 | LMNA (0.49) | LMNAMAPTALOX12KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149569-A1 | MULTIFUNCTIONAL COMPOUNDS FOR USE IN MEDICAL IMAGING AND THERAPY | ANTELOPE SURGICAL SOLUTIONS, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149569-A1 | MULTIFUNCTIONAL COMPOUNDS FOR USE IN MEDICAL IMAGING AND THERAPY | PAICS, BID, OGFR | LMNA 3739/4885MAPT 466/4885ALOX12 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.